Agios Pharma Announces New Clinical Data From Ongoing Phase 1 Study Of AG-221

(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) Saturday announced new clinical data from ongoing Phase 1 study of AG-221, which included 35 patients with IDH2 mutant positive hematologic malignancies. The company said the clinical data continued to show complete and durable remissions in patients with difficult to treat hematologic malignancies.

Safety data showed that AG-221 is well tolerated, with the majority of adverse events reported as mild to moderate. The firm believes that these data support comprehensive investigation of AG-221 in IDH2-mutant positive cancers.

AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein.

According to the company, these data confirm and build upon previously presented data on AG-221's clinical activity, safety profile and unique mechanism of action.

The new data show objective responses in 14 out of 25 evaluable patients on AG-221 and an additional five patients with stable disease. In six patients who achieved a complete remission, evidence of durability was observed, ranging from one to four months in duration.

Agios stated that these promising safety and efficacy data of AG-221 support its plan to initiate four expansion cohorts in the second half of 2014.